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Abstract
Introduction:  Cancer  is  the  leading  cause  of  death  worldwide,  with  8.2  million  deaths  in  2012:
4.7 million  (57%)  male  deaths  and  3.5  million  (43%)  female  deaths.  In  Mexico,  it  ranks  second
as a  cause  of  death  (2007).
Objective:  To  describe  the  most  common  types  of  cancers,  as  well  as  their  trends  over  the
1990--2012  period.
Methods:  Mortality  rates  were  standardised  (ASMR)  by  age  and  gender.  The  annual  percent
change (APC)  was  calculated  using  Poisson  regression  model  and  by  means  of  analysing  time
trends and  variability  on  a  regional  level.  The  Years  of  Potential  Life  Lost  (YPLL)  were  calculated.
Results: ASMR  increased  from  9.7  to  12.2,  from  1990  to  2012.  In  men,  the  most  common  types
of cancer  were:  prostate,  lung  and  stomach  (ASMR  10.4,  8.0  and  5.8,  respectively);  APC  was
of 2.9,  −0.6  and  −0.1,  and  in  women:  breast  (ASMR  9.8  and  APC  2.7),  cervical  (ASMR  between
12.6 and  6.6  and  APC  −2.0)  and  liver  (ASMR  4.9,  APC  1.3).  The  highest  ASMR  was  observed  in
the North  of  Mexico,  mainly  for  lung,  prostate,  breast,  colon,  ovarian  and  pancreatic  cancer.
Discussion:  In  Mexico,  cancer  is  a  major  public  health  problem.  Although  mortality  is  an  indica-
tor of  the  access  and  effectiveness  of  medical  care,  it  is  necessary  to  create  population-based
cancer registries  to  have  basic  information  in  the  planning  and  quality  assessment  of  medical
services such  as  prevention,  early  diagnosis  and  treatment,  as  well  as  to  develop  strategies  to
allocate resources  and  necessities  to  fulﬁl  the  population’s  demand  for  medical  assistance.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Published  by  Masson  Doyma  México
S.A. All  rights  reserved.∗ Corresponding author at: Av. Insurgentes Sur 3700-C Insurgentes Cuicuilco, C.P. 04530, Delegación Coyoacán, México, D.F., Mexico.
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Tendencia  de  la  mortalidad  por  cáncer  en  México:  1990-2012
Resumen
Introducción:  El  cáncer  es  la  primera  causa  de  muerte  a  nivel  mundial,  con  8.2  millones  de
defunciones  en  el  2012:  4.7  millones  (57%)  en  hombres  y  3.5  millones  (43%)  en  mujeres.  En
México, el  cáncer  ocupa  el  segundo  lugar  como  causa  de  muerte  (2007).
Objetivo:  Describirlas  principales  causas  de  mortalidad  por  cáncer  y  su  tendencia  durante  el
periodo 1990-2012.
Métodos:  Se  estandarizaron  las  tasas  de  mortalidad  (ASMR)por  edad  y  sexo.  Analizandosu  ten-
dencia temporal  y  variabilidad  regional,  se  evaluóel  porcentaje  anual  de  cambio  (APC)  mediante
el modelo  de  regresión  log-lineal  de  Poisson.  Se  calculó  el  índice  de  an˜os  de  vida  potencialmente
perdidos  (IAVPP).
Resultados:  LaASMRincrementó  de  9.7  a  12.2,  de  1990  al  20012.  Los  tipos  decáncermás
frecuentes  en  el  hombre  fueron  próstata,  pulmón  y  estómago  (ASMR  de  10.4,  8.0  y  5.8  respec-
tivamente);  el  APCfue  de  2.9,  -0.6,  y  -0.1,  y  en  la  mujer,  el  de  mama  (ASMRde  9.8  y  APC  de
2.7), el  cervicouterino  (ASMR  de  12.6  a  6.6  y  APC  de  -2.0)  y  el  de  hígado  (ASMR  de  4.9,  APC
1.3). En  el  Norte  del  país  se  observaron  mayores  ASMRprincipalmente  para  cáncer  de  pulmón,
próstata,  mama,  colon,  ovario  y  páncreas.
Discusión:  En  México,  el  cáncer  es  un  importante  problema  de  salud  pública.  Aunque  la  mortal-
idad es  un  indicador  del  acceso  y  eﬁcacia  de  la  atención  médica,  es  necesaria  la  creación  de  los
registros de  cáncer  de  base  poblacional,  para  contar  con  información  básica  en  la  planiﬁcación
y evaluación  de  la  calidad  de  los  servicios  médicos,  tales  como  la  prevención,  diagnóstico  y
tratamiento  precoz,  así  como  el  desarrollo  de  estrategias  para  la  distribución  de  los  recursos  y
necesidades  para  satisfacer  la  demanda  de  atención  médica  de  la  población.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Publicado  por  Masson  Doyma  México
S.A. Todos  los  derechos  reservados.
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introduction
ince  last  century,  cancer  has  been  considered  a  common
isease  that  became  a  major  public  health  problem  on  a
lobal  scale.1 In  addition  to  causing  a  high  number  of  deaths
ach  year,  it  creates  huge  economic,  social  and  emotional
urdens.  Data  from  the  World  Health  Organization  (WHO)
fﬁrms  cancer  is  the  leading  cause  of  death  across  the
orld  and  the  second  one,  after  cardiovascular  diseases,
n  underdeveloped  countries  (Africa,  Asia,  Central  Amer-
ca  and  South  America)  where  it  accounts  for  more  than
0%  of  registered  deaths.  This  is  associated  to  strategy  deﬁ-
iencies  for  the  prevention,  diagnosis  and  treatment2 of  the
isease.3,4 According  GLOBOCAN  data  from  2012,  there  were
4.1  million  new  cancer  cases  across  the  world  and  8.2  mil-
ion  deaths,  which  represented  13%  of  the  total  of  deaths.
rojections  indicate  that  the  number  of  deaths  caused  by
ancer  in  America  will  rise  from  1.3  million  to  2.1  million
n  2030.  Likewise,  the  number  of  new  cases  is  expected  to
ise  by  67%  in  Latin  America  and  the  Caribbean  (1.8  million
er  year);  this  estimates  are  higher  than  the  ones  for  North
merica  (41%).5,6
In  the  last  report,  ‘‘Cancer  in  the  Americas:  Country
roﬁles  2013’’, carried  out  by  the  Pan  American  Health
rganization  (PAHO)  and  the  World  Health  Organization
WHO),  it  is  reported  that  mortality  caused  by  all  types  of
ancer  is  decreasing  in  at  least  nine  countries  of  America
Argentina,  Brazil,  Canada,  Chile,  United  States,  Mexico,
icaragua,  Paraguay  and  Venezuela);  in  the  rest,  the  trends
n  mortality  due  to  some  types  of  cancer  is  still  on  the  rise.7
i
i
cMost  deaths  in  Latin  America  are  caused  by  lung,
rostate,  breast  and  colorectal  cancer.  There  are  some  vari-
tions  evident,  depending  on  the  affected  subregion.  For
nstance,  in  North  America  lung  cancer  is  the  main  cause
f  death  in  women,  whereas  in  Central  America  one  of  the
ypes  of  cancer  with  the  highest  mortality  rates  is  cervical
ancer  (which  caused  over  35,600  deaths  in  2012);  in  the
aribbean,  the  incidence  and  mortality  rates  due  to  prostate
ancer  are  signiﬁcantly  higher  than  in  other  subregions;
tomach  cancer  is  the  ﬁfth  cause  of  death  for  both  genders
n  Latin  American  and  the  Caribbean  countries,  whereas  in
orth  America  it  is  not  even  listed  within  the  ﬁrst  15  causes
f  death.5,6
In  Mexico,  the  historical  behaviour  of  cancer  mortality
as  had  a  rising  trend.  Since  1999,  the  numbers  have  already
een  considered  alarming,  given  that  there  were  53.6  deaths
eported  for  every  100,000  inhabitants.  This  number  rose  to
5.2  in  2001,  almost  triple  what  was  reported  in  1931  (19.9
eaths  every  100,000  inhabitants).  For  this  year,  cancer  was
lready  placed  as  the  second  leading  cause  of  death  and  it
omprised  11.8%  of  the  total  of  deaths.8,9
According  to  the  data  published  by  the  National  Institute
f  Statistics  and  Geography  (Instituto  Nacional  de  Estadis-
ica  y  Geograﬁa,  INEGI)  in  2007,  cancer  was  still  the  second
eading  cause  of  death  in  the  country  (some  reports  placed
t  as  third  cause),  after  diabetes  mellitus  and  before  heart
schaemic  diseases.10 Cancer  was  the  leading  cause  of  death
n  women  between  the  age  of  30  and  59,  but  it  was  second
n  women  between  the  age  of  15  and  29.  It  was  the  third
ause  of  death  in  men  over  the  age  of  30.11
87
Table  1  Proportional  mortality  rate  due  to  malignant
tumours,  Mexico  1990--2012.
Year  Total  deaths  Deaths  due  to
malignant  tumours
PMRa
1990  422,803  41,168  9.7
1991 411,131  41,985  10.2
1992 409,814  43,692  10.7
1993 416,335  44,951  10.8
1994 419,074  46,423  11.1
1995 430,278  48,222  11.2
1996 436,321  49,916  11.4
1997 440,437  51,254  11.6
1998 444,665  52,670  11.8
1999 443,950  53,662  12.1
2000 437,667  54,996  12.6
2001 443,127  56,201  12.7
2002 459,687  58,599  12.7
2003 472,140  60,046  12.7
2004 473,417  61,248  12.9
2005 495,240  63,128  12.7
2006 494,471  63,888  12.9
2007 514,420  65,112  12.7
2008 539,530  67,049  12.4
2009 564,673  68,454  12.1
2010 592,020  70,240  11.9
2011 590,693  71,350  12.1
2012 602,354  73,240  12.2
Total 10,954,247  1,307,494  11.9
Source:  Based on deaths 1990--2012, Information in Health Sys-
m
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According  to  the  data  published  in  the  Histopatologic
Register  of  Malignant  Neoplasms  (Registro  Histopatologico
de  Neoplasias  Malignas,  RHNM)  in  2011,  cancer  incidence
nationwide  maintained  a  rising  trend  among  deaths  from
1980  to  1989  (41.8  to  51.1  per  105),  with  a  fall  in  1990  (49.0
per  105);  its  rise  soared  from  1994  to  2008,  with  rates  that
went  from  51.4  to  66.6  per  105,  causing  71,074  deaths.12
In  2012,  Aldaco-Sarvide  et  al.13 reported  that  a  total  of
592,018  people  passed  away  in  the  year  2010.  Out  of  these
deaths,  74,685  were  caused  by  cancer.  This  corresponds  to
12.6%  of  the  total  of  deaths.
Recently,  according  to  the  2013  PAHO/WHO  report,  can-
cer  mortality  rates  in  Mexico  decreased  during  the  years
2009  and  2010.4 33,263  male  deaths  and  34,745  female
deaths  were  registered,  with  distinct  rising  trends  within
the  population  over  the  age  of  30  and  elevated  death  rates
for  the  majority  of  the  types  of  cancer.
Although  the  problem  cancer  represents  on  a  global  scale
can  be  seen  in  a  general  way  through  international  reg-
istries,  data  from  Mexico  is  paltry  and  access  to  be  able  to
determine  its  real  impact  on  health  more  precisely  is  dif-
ﬁcult.  For  this  reason,  and  given  the  need  to  have  more
information  available  that  supports  the  understanding  of
the  evolution  and  state  of  cancer  in  our  country,  this  study
has  been  carried  out.  It  describes  the  trend  and  epidemio-
logic  behaviour  of  the  ten  leading  causes  of  death  by  cancer
within  the  Mexican  population  from  1990  to  2012.
Methods
Data  on  deaths  due  to  malignant  tumours  was  gathered  from
ofﬁcial  databases  from  1990  to  2012,  which  were  obtained
from  death  certiﬁcates  validated  by  the  National  Institute
of  Statistics  and  Geography  (INEGI)14 and  published  by  the
National  Health  Information  System  (NHIS).15 The  2010--2050
projections  for  the  population  of  Mexico  were  also  taken
into  account  for  this  period,  which  were  published  by  the
National  Population  Council  (Consejo  Nacional  de  Poblacion,
CONAPO)16 and  the  International  Classiﬁcation  of  Diseases
was  also  used  (CIE-10).17 A  descriptive,  univariate  analysis
was  carried  out  by  gender,  age,  state  and  type  of  cancer
as  cause  of  mortality,  and  a  bivariate  analysis  to  com-
pare  mortality  rates  by  gender,  age  group  and  state.  The
national  annual  mortality  rate  was  calculated  from  1990  to
2012,  as  well  as  the  global  cancer  mortality  rate  for  the
same  period.  The  mortality  ratio  between  men  and  women
was  calculated.  The  evolution  of  mortality  was  obtained
by  calculating  the  ratio  between  rates;  subsequently,  the
standardisation  of  rates  was  performed  by  age  (ASMR)  for
the  ten  leading  causes  of  death  by  cancer  by  year  and  by
gender,  via  the  direct  method18 and  Doll  et  al.  population,
modiﬁed  by  Segui.19 All  mortality  rates  were  calculated  by
100,000  inhabitants.  The  evolution  of  cancer  mortality  over
time  and  the  interstate  ﬂuctuation  was  expressed  as  the
annual  percentage  change  (APC)  using  the  Poisson  regression
model.  To  determine  the  magnitude  of  the  leading  causes
of  death  due  to  cancer  by  state  for  the  study  period,  the
ASMR  was  classiﬁed  into  levels,  very  high,  high,  medium
and  low  according  to  the  quartile  method.  The  results  are
provided  with  their  conﬁdence  intervals  (CI)  to  95%.  To
make  comparisons  between  states  and  to  assess  premature
p
w
item (SINAIS). Health Secretary, Mexico.
a Proportional mortality rate.
ortality  due  to  cancer,  the  Years  of  Potential  Life  Lost
YPLL)  was  calculated.20,21 Microsoft  Access  2003  and  INTER-
OOLED  STATA  12  statistical  packages  for  Windows  were  used
or  the  calculations.
esults
uring  the  study  period,  out  of  10,954,247  deaths  registered
ationwide,  1,307,494  (11.9%)  were  caused  by  some  type  of
ancer.  As  shown  in  Table  1, deaths  caused  by  cancer  rose
n  absolute  numbers  from  41,168  (9.7%)  in  1990  to  73,240
12.2%)  in  2012.
With  respect  to  mortality  due  to  cancer  and  age  (grouped
nto  ﬁve-year  periods),  in  the  year  2012  there  was  a  rising
rend  as  people  got  older,  which  became  more  evident  for
eople  over  the  age  of  40.  When  comparing  the  risk  of  death
etween  men  and  women  by  age  group,  this  was  higher  for
en  in  early  stages  of  life  (under  the  age  of  30)  and  over
he  age  of  65.  Conversely,  the  risk  of  death  for  women  was
igher  between  the  ages  of  30  and  64  (Fig.  1).
When  analysing  the  leading  causes  of  death  by  gender,
here  was  a  signiﬁcant  rise  in  mortality  rates  within  the
ale  population  over  the  age  of  60  and  within  the  female
opulation  over  the  age  of  40  (Fig.  2).
In  the  comparative  analysis  (1990  vs  2012)  the  results
ere  the  following.  The  male  mortality  rate  from  1990  rose
n  2012  from  46.6  to  63.1  per  105;  this  situation  changed
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Figure  1  Mortality  due  to  malignant  tumours,  Mexico  2012.  *Rate  per  105.
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fter  standardising  the  rates  by  age.  There  was  a  fall  in  the
SMR  from  84.3  (95%  CI,  61.00--85.0)  to  67.7  per  105 (95%
I,  67.1--68.4).  The  average  life  expectancy  rose  from  age
1  to  65  and  the  APC  was  of  1.4  (95%  CI,  1.4--1.5).  The  ten
eading  causes  of  death  in  males  were:  prostate  cancer  with
n  ASMR  of  10.4  per  105,  lung  and  bronchi  cancer  with  an
SMR  of  8.0  per  105,  stomach  cancer  with  an  ASMR  of  5.8
er  105,  liver  cancer  with  an  ASMR  of  5.4  per  105,  colon
ancer  with  an  ASMR  of  4.0  per  105,  pancreas  cancer  with
n  ASMR  of  3.7  per  105,  lymphoid  leukaemia,  brain  cancer,
idney  cancer  and  larynx  cancer  with  an  ASMR  of  2.0,  2.2,
.2  and  1.5  per  105,  respectively.  The  ﬁrst  ﬁve  leading  causes
omprised  49%  of  the  total  of  deaths  and  the  subsequent  ﬁve
7%  of  the  deaths.  Thus,  the  ten  types  of  cancer  mentioned
bove  comprised  66%  of  total  deaths.
The  ASMR  trends  during  the  study  period  ﬂuctuated
ccording  to  the  type  of  cancer.  Colon  cancer  ASMR  (4.0
a
w
cer  105),  brain  cancer  ASMR  (2.2  per  105) and  lymphoid
eukaemia  ASMR  (2.0  per  105)  were  higher  in  2012  than  in
990.  Conversely,  lung  and  bronchi  cancer  ASMR  (16.1  per
05),  stomach  cancer  ASMR  (10.2  per  105)  and  larynx  can-
er  ASMR  (2.7  per  105)  declined  almost  by  50%  in  2012  (8.0,
.8,  1.5  per  105,  respectively).  The  types  of  cancer  that
emained  with  very  similar  mortality  rates  were  prostate
ancer  (ASMR  from  10.9  to  10.4  per  105)  and  pancreas  cancer
ASMR  from  3.9  to  3.7  per  105) (Table  2).
In  women,  the  mortality  rate  rose  from  51.1  to  62.2
eaths  per  105. A  similar  trend  was  seen  when  standard-
sing  rates  by  age:  the  ASMR  rose  from  58.5  to  63.1  (95%  CI,
2.4--63.7)  deaths  per  105.The  average  life  expectancy  rose  from  age  61  to  63  with
n  APC  of  0.9.  The  most  common  types  of  cancer  in  2012
ere:  breast  cancer  with  an  ASMR  of  9.8  per  105, cervical
ancer  with  an  ASMR  of  6.6  per  105, liver  cancer  with  an
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ASMR  of  4.9  per  105,  stomach  cancer  with  an  ASMR  of  4.3  per
105,  lung  and  bronchi  cancer  with  an  ASMR  of  3.8  per  105,
ovarian  cancer  with  an  ASMR  of  3.5  per  105,  pancreas  cancer,
colon  cancer  and  lymphoid  leukaemia  with  an  ASMR  of  3.4,
3.1  and  1.6  per  105 cases,  respectively.  The  pattern  was  very
similar  to  the  one  seen  in  men:  the  ﬁrst  ﬁve  causes  of  death
mentioned  above  represented  46%  of  the  total  of  deaths  in
2012,  and  the  subsequent  ones  represented  18%.  Overall,
they  comprised  66%  of  the  total  of  deaths  from  cancer  in
women.
In  2012,  there  was  a  rising  trend  in  mortality  in  women
for  the  following  types  of  cancer:  breast  cancer  (ASMR  from
6.6  to  9.8  per  105),  which  after  being  in  second  place  in
1990  placed  ﬁrst  in  2012;  ovarian  cancer  (ASMR  from  2.1  to
3.5  per  105),  colon  cancer  (ASMR  from  1.4  to  3.1  per  105),
pancreas  cancer  (ASMR  from  2.6  to  3.4  per  105)  and  lym-
phoid  leukaemia  (ASMR  from  1.1  to  1.6  per  105).  There  was
a  decreasing  trend  for:  cervical  cancer  (ASMR  from  12.6  to
6.6  per  105),  which  went  from  the  ﬁrst  to  the  second  place;
stomach  cancer  (ASMR  from  4.8  to  4.3  per  105),  and  lung  and
bronchi  cancer  (ASMR  from  4.1  to  3.8  per  105).
w
A
JAs  for  mortality  by  state,  there  was  no  homogeneous
istribution  in  the  ASMRs.  The  following  states  had  higher
ortality  rates  in  men:  Sonora,  Baja  California  Sur,  Chi-
uahua,  Nuevo  Leon  and  Sinaloa  with  an  ASMR  of  95.47,
4.83,  84.11,  82.88,  82.53,  cases  per  105, respectively.  Tlax-
ala  ranked  last  with  an  ASMR  of  53.43  cases  per  105 and  the
ational  death  rate  was  of  94.83  per  105 inhabitants.
There  were  also  some  differences  in  the  distribution  of
ates  by  state  and  gender.  In  women,  the  higher  mortal-
ty  rates  were  for  Colima  (78.24  cases  per  105),  Sonora
71.82  cases  per  105),  Coahuila  (71.02  cases  per  105),  Baja
alifornia  (70.42  cases  per  105)  and  Nuevo  Leon  (70.24  cases
er  105).  Durango  ranked  last  with  an  ASMR  of  50.69  cases
er  105.  The  national  rate  was  of  123.53  deaths  per  105
nhabitants.
ASMR  distribution  of  the  main  types  of  cancer  by  state
2012)  is  shown  in  Figs.  3  and  4.
Calculated  by  age,  the  national  rate  for  prostate  cancer
as  10.4  cases  per  105 men,  and  the  states  with  the  highest
SMR  of  2012  were:  Aguascalientes  (15.8),  Nayarit  (14.2),
alisco  (13.7),  Colima  (13.5)  and  Sinaloa  (13.4).  The  lowest
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Table  2  Mortality  due  to  malignant  tumours,  Mexico  1990--2012.
Description  Death
1990
Mortality
rates
ASMR  95%  CI  ADD  Death
2012
Mortality
rates
ASMR  95%  CI  ADD  APC  95%  CI
Males
Prostate  2322  5.6  10.9  10.7  11.1  76  5908  10.3  10.4  10.2  10.7  77  2.9  2.6  3.1
Bronchi and  lung  3443  8.3  16.1  15.8  16.4  67  4140  7.2  8.0  7.8  8.2  70  −0.6  −0.8  −0.4
Stomach 2227  5.4  10.2  10.0  10.4  67  2981  5.2  5.8  5.6  6.0  66  −0.1  −0.3  0.2
Liver 1375  3.3  6.3  6.1  6.5  66  2757  4.8  5.4  5.2  5.5  69  1.8  1.5  2.1
Bowel 550  1.3  2.5  2.4  2.6  67  2034  3.6  4.0  3.8  4.1  64  4.6  4.2  5.1
Pancreas 852  2.1  3.9  3.8  4.1  66  1836  3.2  3.7  3.5  3.8  67  2.1  1.7  2.5
Lymphoid leukaemia  550  1.3  1.4  1.3  1.5  27  1139  2.0  2.0  1.9  2.1  34  1.3  0.8  1.8
Brain 515  1.1  1.9  1.8  2.0  44  1126  2.0  2.2  2.0  2.3  51  2.2  1.7  2.6
Kidney 446  2.4  4.4  4.2  4.5  59  1114  1.9  2.2  2.1  2.3  63  2.8  2.3  3.3
Larynx 566  1.4  2.7  2.6  2.8  68  747  1.3  1.5  1.4  1.6  70  −0.2  −0.7  0.3
Non-speciﬁc 1016  1.2  1.9  1.8  2.0  60  1001  1.8  1.9  1.8  2.0  63  −0.9  −1.3  −0.5
Rest 5454  13.2  22.1  21.7  22.4  58  11,321  19.8  21.2  20.9  21.6  61  1.9  1.8  2.1
Total 19,316  46.6  84.3  83.7  85.0  61  36,104  63.1  67.7  67.1  68.4  65  1.4  1.4  1.5
Females
Breast 2198  5.2  6.6  6.4  6.9  56.9  5612  9.4  9.8  9.5  10.0  59  2.7  2.5  2.9
Cervical uterine  4257  10.1  12.6  12.3  12.9  57.7  3840  6.4  6.6  6.4  6.8  59  −2.0  −2.2  −1.8
Liver 1531  3.6  4.0  3.9  4.2  66.1  2890  4.8  4.9  4.8  5.1  69  1.3  1.0  1.6
Stomach 1943  4.6  4.8  4.6  5.0  67.2  2593  4.3  4.3  4.2  4.5  46  −0.3  −0.5  0.0
Bronchi and  lung  1543  3.7  4.1  3.9  4.3  66.8  2238  3.8  3.8  3.7  4.0  69  0.1  −0.2  0.4
Ovary 715  1.7  2.1  2.0  2.2  57.6  1995  3.3  3.5  3.4  3.7  59  3.1  2.7  3.5
Pancreas 955  2.3  2.6  2.4  2.7  66.4  1993  3.3  3.4  3.3  3.6  69  1.8  1.4  2.1
Bowel 601  1.4  1.4  1.3  1.5  67.2  1859  3.1  3.1  3.0  3.3  67  3.6  3.2  4.1
Lymphoid leukaemia  446  1.1  1.1  1.0  1.2  27.2  956  1.6  1.6  1.5  1.7  36  1.9  1.4  2.4
Non-speciﬁc biliary  tract  647  1.5  1.7  1.6  1.9  67.8  591  1.0  1.0  0.9  1.1  70  −2.0  −2.5  −1.5
Non-speciﬁc 1079  2.6  2.9  2.8  3.1  59.5  984  1.6  1.7  1.6  1.8  64  −2.0  −2.4  −1.6
Rest 5548  13.2  14.5  14.2  14.8  59.7  11,552  19.4  19.4  19.1  19.8  63  1.8  1.6  1.9
Total 21,463  51.1  58.5  57.9  59.2  61.3  37,103  62.2  63.1  62.4  63.7  63  0.9  0.8  1.0
Source:  Based on deaths 1990--2012, Information in Health System (SINAIS). Health Secretary, Mexico.
Population estimations; National Population Consensus (CONAPO), Mexico 1990--2012.
Mortality rate, rate per 105; ASMR, age-standardised mortality rates in people greater than 20 years; 95% CI, 95% conﬁdence intervals; ADD, mean age of death; APC, annual percentage
change.
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Figure  3  ASMR*  geographical  distribution  of  principal  malignant  tumours  in  males,  Mexico  2012.  *Mortality  rate  standardised  by
age.
Source:  Based  on  deaths  2012.  National  System  of  Information  in  Health  (SINAIS).  Health  Secretary,  Mexico.  Population  estimations;
National Population  Consensus  (CONAPO),  Mexico  2012.
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(ource:  Based  on  deaths  2012.  National  System  of  Information  in
ational Population  Consensus  (CONAPO),  Mexico  1990--2012.
ates  were  for  the  states  of  Hidalgo  (7.9),  Yucatan  (7.2)  and
uintana  Roo  (6.7).
The  states  with  the  highest  ASMR  for  breast  cancer
national  rate  of  9.8)  were:  Mexico  City  (14.7),  Nuevo  Leon
14.0),  Baja  California  (13.6),  Baja  California  Sur  and  Colima
13.3);  the  lowest  rates  were  for  Guerrero  (5.8),  Campeche
4.9)  and  Oaxaca  (4.3).
The  states  with  the  highest  ASMR  for  lung  and  bronchi
ancer  (national  rate  of  8.0  for  men)  were  Baja  California
ur  (19.1),  Sinaloa  (18.1),  Sonora  (17.7),  Chihuahua  (14.1)
nd  Nuevo  Leon  (13.0);  and  the  states  with  the  lowest  rates
ere  Oaxaca  (3.7),  Hidalgo  (3.6)  and  Tlaxcala  (2.8).
The  states  with  the  highest  ASMR  for  cervical  cancer
national  rate  of  6.6)  were:  Colima  (12.5),  Chiapas  (9.4),
ucatan  and  Sonora  (8.4),  Campeche  (8.2)  and  Morelos  (8.1),
ainly.  The  lowest  rates  were  for  the  states  of  Durango
3.9),  Zacatecas  (3.6)  and  Hidalgo  (3.5).
The  states  with  the  highest  ASMR  for  stomach  cancer
national  rate  of  5.8  for  men  and  4.3  for  women)  were  the
ollowing:  for  men  and  women,  Chiapas  (9.5  and  7.0),  Sonora
8.3  and  4.3),  Oaxaca  (7.4  and  5.7),  Mexico  City  (7.4  and
.9)  and  Campeche  (7.4  and  5.7);  the  lowest  rates  were
or  the  states  of  Nuevo  León  (4.3  and  3.9),  Nayarit  (4.0
nd  2.7),  Durango  (4.6  and  2.1),  Coahuila  (3.6  and  3.9)  and
guascalientes  (1.8  for  women).Fig.  5  shows  the  premature  mortality  rate  by  type  of  can-
er,  gender  and  state.  Mexico  City,  Sonora,  Baja  California
ur,  Veracruz  and  Chihuahua  had  higher  premature  mortality
ates  for  men,  with  1.32,  1.30,  1.29,  1.28  and  1.20  YPLL.
r
5
rlth  (SINAIS).  Health  Secretary.  Mexico.  Population  estimations;
The  states  with  the  highest  premature  mortality  rates
or  women  were  Mexico  City  (YPLL  1.25),  Chihuahua  (YPLL
.17),  Baja  California  (YPLL  1.15),  Chiapas  (YPLL  1.12)  and
onora  (YPLL  1.10).
iscussion
he  importance  cancer  has  had  throughout  history  is  not  only
ue  to  the  progressive  growth  of  its  incidence  and  mortality
ates,  but  it  also  to  the  economic  impact  that  its  treat-
ent  generates  in  healthcare  services  and  in  the  patients’
amilies.
In  Mexico,  just  as  in  the  rest  of  the  world,  cancer  has
isen  signiﬁcantly  among  the  population,  with  a  clear  rising
rend  that  generates  a  real  issue  in  public  health.
In  the  2013  PAHO/WHO  report,7 it  is  mentioned  that  Mex-
co  is  part  of  the  nine  countries  with  decreasing  trends  for
ancer  mortality.  However,  the  results  from  this  study  show
 reduction  in  the  mortality  rates  of  some  types  of  can-
er  only,  such  as  cervical  and  lung  cancer.  Within  the  study
eriod  there  was  a  clear  rising  trend  in  global  cancer  mortal-
ty,  represented  in  the  proportional  mortality  ratio  of  2012
12.2%)  compared  to  the  one  from  1990  (9.7%).Likewise,  there  was  also  an  increase  in  the  raw  mortality
ate  by  gender  from  46.6  to  63.1  per  105 in  men  and  from
1.1  to  63.1  per  105 in  women.  Although  when  standardising
ates  by  age,  there  was  still  a  rising  trend  for  women  with
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ASMR  from  58.5  to  63.1  per  105,  in  men,  the  ASMR  decreased
from  84.3  to  67.7  per  105.
A  similar  scenario  was  reported  both  in  the  Aldaco  et  al.13
study  during  the  2000--2010  period,  and  in  the  Histopatho-
logic  Register  of  Malignant  Neoplasms  from  2011.12 In  the
ﬁrst  one,  cancer  mortality  rates  rose  from  59.3  to  66.5  per
105,  and  in  the  second  one,  the  increment  went  from  41.8
to  62.8  for  the  1980--2008  period.
The  ratio  between  mortality  rates  from  men  and  women
was  very  narrow,  with  a  slight  predominance  in  men  under
the  age  of  30  (1.4:1)  and  over  the  age  of  65  (1.15:1).  Con-
versely,  women  between  the  age  of  30  and  64  (1:1.3)  showed
a  higher  risk  of  death.  This  analysis  can  be  an  important  tool
to  measure  the  impact  cancer  has  on  the  population.
The  correspondence  between  the  risk  of  death  by  can-
cer  and  age  is  already  well  known.  Mortality  rates  increase
at  older  ages,  a  fact  that  is  also  seen  in  the  results  of  this
study.  This  phenomenon  goes  hand  in  hand  with  the  increas-
ing  proportion  of  older  adults,  and  it  can  be  explained  by
itself  due  to  the  ageing  of  the  population  Mexico  is  expe-
riencing  since  a  few  decades  ago.  Therefore,  we  must  not
overlook  the  fact  that  the  result  of  the  demographic  tran-
sition  is  in  turn  the  reﬂection  of  the  reduction  in  fertility
rates  and  mortality  itself.
The  ﬂuctuations  in  mortality  by  age  and  gender  groups
are  indiscriminately  associated  with  the  shifting  of  those
types  of  cancer  that  caused  more  deaths  in  the  past.
For  instance,  for  breast  cancer,  which  ranked  ﬁrst  in  2012
as  leading  cause  of  death  and  which  took  cervical  cancer’s
place,  the  ASMR  rising  trend  becomes  more  evident  over
the  age  of  30,  when  the  risk  for  cancer  is  more  common  for
women.  The  average  life  expectancy  was  59  years.
Conversely,  the  increase  in  ASMR  becomes  more  evident
for  prostate  cancer  over  the  age  of  65  (ADD  77  years).  This
type  of  cancer  represented  the  prime  cause  of  death  among
the  male  population,  taking  lung  and  bronchi  cancer’s  place.
There  were  higher  ASMR  at  younger  ages  (35--39  years)  in
women  for  stomach  cancer,  although  there  was  a  decreasing
trend,  in  comparison  to  men  (65--69  years),  with  ADDs  of  46
and  66  years,  respectively.
Another  interesting  fact  is  the  differences  in  ASMRs  by
states.  The  highest  rates  for  lung  and  bronchi  cancer,  colon
cancer,  breast  and  ovarian  cancer  were  in  some  of  the  states
from  the  North  of  the  country  (Baja  California,  Sonora,  Chi-
huahua,  Coahuila,  Nuevo  Leon,  Tamaulipas).  In  the  states
from  the  South  (Chiapas,  Oaxaca,  Campeche  and  Yucatán),
the  higher  rates  were  for  cervical,  stomach  and  liver  cancer.
The  presence  of  cancer  in  the  centre  of  the  country  was  het-
erogeneous  and  contrasting  in  their  ASMRs;  Mexico  City  had
the  highest  YPLL,  both  for  men  (1.32)  and  women  (1.25).
This  scenario,  which  is  undoubtedly  associated  with
the  individual  characteristics  of  the  population,  differ-
ent  lifestyles,  marginalisation,  sociocultural  level,  poverty
and/or  economic  resources  allocated  for  healthcare,  shows
that  the  link  between  cancer  and  risk  factors  associated
to  its  mortality  need  to  be  tackled  in  a  more  precise
manner.
Likewise,  and  regardless  of  the  beneﬁts  obtained  with
the  current  programmes  and  strategies  to  control  cancer,
there  must  be  more  epidemiologic  studies  that  can  provide
other  indicators,  such  as  the  incidence,  death  or  survival
rate,  and  that  support  understanding  of  the  determinants93
nvolved,  to  study  in  depth  and  have  a  better  knowledge  of
he  real  impact  of  this  problem  in  our  country.
One  of  the  international  models  that  can  enable  us
o  have  an  idea  of  the  impact  cancer  has  across  the
orld  and  in  our  country  is  the  GLOBOCAN  registry.6
owever,  this  system  does  not  necessarily  reﬂect  reality,
ince  it  is  based  on  estimates  of  the  situation  and  uses
ources  that  do  not  necessarily  reﬂect  the  current  state  of
ancer.
In  spite  of  the  complexity  that  the  interpretation  of  the
ata  gathered  in  the  mortality  registries  generates,  partic-
larly  since  the  lack  of  speciﬁcs  that  determine  the  basic
auses  of  death  in  death  certiﬁcates  can  affect  their  valid-
ty  and  reliability,  analysis  of  mortality  can  serve  to  a  great
xtent  as  a  tracer  indicator  of  the  access  to  healthcare
ervices.  At  the  same  time  it  can  provide  important  data
o  analyse  the  epidemiologic  scenario  of  cancer  mortality,
stimate  the  risk  of  death  or  survival  among  the  popula-
ion,  and  consider  various  scenarios  to  design  and  evaluate
rogrammes  and  health  policies.
While  we  cannot  overlook  the  fact  that  even  though  it  is
ot  enough  to  analyse  mortality  in  isolation  to  determine  the
eal  situation  that  cancer  represents  in  healthcare  services
nd  in  the  population,  it  must  be  pointed  out  that  the  results
f  the  analysis,  even  if  to  a  certain  extent  they  limit  a  clear
ssessment  of  the  problem,  are  the  best  approach  to  reality
nd  facilitate  decision-making  in  healthcare.
To  conclude,  it  is  essential  to  strive  for  an  ongoing
mprovement  of  the  quality  of  registries  to  reduce  poten-
ial  errors  that  can  limit  the  analysis  of  mortality  and,  of
ourse,  to  not  overlook  the  clear  need  to  have  population-
ased  regional  epidemiologic  cancer  registries,  which  will
nable  us  to  understand  the  real  situation  related  to  cancer
n  our  country  and  support  better  decision-making  within
rogrammes  and  strategies  that  aim  at  training  for  early
iagnosis  and  timely  treatment.  The  impact  will  be  reﬂected
n  the  incidence  and  mortality  of  cancer  over  the  coming
ears.
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